Having trouble accessing articles? Reset your cache.

Catena idebenone: Additional Phase II data

Additional data from the double-blind, international Phase II RHODOS trial in 39 evaluable patients who had severely impaired color contrast sensitivity at baseline showed that 900 mg/day Catena significantly improved

Read the full 301 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE